I have enough information from the textbooks and my knowledge to write comprehensive answers for all remaining questions. Here they are:
Remaining Questions - University Exam Answers
SHORT ANSWER QUESTIONS (1 mark each)
Q1. Describe the inheritance pattern of Hemophilia A and explain why it preferentially affects males (1 mark)
Answer:
Inheritance Pattern: Hemophilia A is inherited as an X-linked recessive disorder (20% of cases arise from new spontaneous mutations).
Why it preferentially affects males:
- The gene for Factor VIII (deficient in Hemophilia A) is located on the X chromosome
- Males are hemizygous (XY) - they have only ONE X chromosome, so a single defective copy of the gene causes disease
- Females are heterozygous carriers (X^H X^h) - they have TWO X chromosomes; the normal allele on the second X compensates, so they are usually unaffected carriers
- A female would need TWO defective copies (X^h X^h) to manifest the disease - this is extremely rare
Punnett Square to draw:
Carrier Mother (X^H X^h) × Normal Father (X^H Y)
Daughters: X^H X^H (normal), X^H X^h (carrier)
Sons: X^H Y (normal), X^h Y (affected)
- 50% of sons are affected; 50% of daughters are carriers
Q2. Platelet count of 20,000/cumm in a young woman - What is this condition called? List 4 causes
Answer:
Condition: This is called Thrombocytopenia (normal platelet count = 1,50,000 - 4,00,000/cumm)
At 20,000/cumm with a young woman, the most likely diagnosis is Immune Thrombocytopenic Purpura (ITP)
4 Causes of Thrombocytopenia:
| Mechanism | Causes |
|---|
| Decreased production | Aplastic anemia, Leukemia infiltrating bone marrow, Megaloblastic anemia (B12/folate deficiency), Drug-induced (chemotherapy) |
| Increased destruction | ITP (autoimmune - most common in young women), SLE, Drug-induced (heparin - HIT), DIC |
| Increased sequestration | Hypersplenism (spleen traps platelets) |
| Dilutional | Massive blood transfusion |
4 causes to list:
- ITP (Immune Thrombocytopenic Purpura) - autoantibodies (IgG) against platelet GPIIb/IIIa
- SLE (Systemic Lupus Erythematosus)
- Aplastic anemia (decreased production)
- Drug-induced thrombocytopenia (e.g., heparin, quinine, sulfonamides)
Q3. Why is splenectomy beneficial in cases of Chronic ITP? (1 mark)
Answer:
Splenectomy is beneficial in chronic ITP for TWO main reasons:
1. Removes the major site of platelet destruction:
- In ITP, autoantibodies (IgG) coat platelets via GPIIb/IIIa antigens
- The spleen is the primary site where these antibody-coated platelets are recognized and destroyed by splenic macrophages (reticuloendothelial system)
- Removing the spleen eliminates this destruction
2. Removes the major site of autoantibody production:
- The spleen contains the B-lymphocytes that produce anti-platelet IgG antibodies
- Splenectomy reduces the antibody burden, allowing platelet survival to improve
Result: After splenectomy, platelet count rises in ~60-70% of patients. It is used as second-line therapy when steroids and IVIG fail.
SHORT ESSAY TYPE QUESTIONS (5 Marks each)
Essay Q1. Tabulate differences between Chronic Myeloid Leukemia (CML) and Chronic Lymphocytic Leukemia (CLL) (5 marks)
Write this table in your exam:
| Feature | CML | CLL |
|---|
| Cell of origin | Myeloid stem cell (granulocytic series) | B-lymphocyte (mature) |
| Age | 25-60 years (middle age) | >50 years (elderly) |
| Sex | Male > Female | Male > Female |
| Peripheral smear | Leukocytosis with ALL stages of myeloid maturation (myeloblasts to mature neutrophils) - "myeloid spectrum"; basophilia prominent | Mature small lymphocytes + Smudge/basket cells (pathognomonic) |
| WBC count | Markedly elevated (often >1,00,000/cumm) | Elevated (10,000-2,00,000/cumm) of mature lymphocytes |
| Cytogenetics | Philadelphia chromosome t(9;22) → BCR-ABL fusion gene (95% cases) | No Philadelphia chromosome; del 13q (most common), del 11q, del 17p, trisomy 12 |
| Bone marrow | Hypercellular - all myeloid precursors, ↑ megakaryocytes | Hypercellular - replaced by mature small lymphocytes |
| Spleen | Massively enlarged (hallmark finding) | Moderately enlarged |
| Lymph nodes | Mildly enlarged | Generalized lymphadenopathy (prominent) |
| Leukocyte Alkaline Phosphatase (LAP) score | Markedly decreased (low) | Normal or elevated |
| Blasts in peripheral smear | <10% (chronic phase) | Absent (mature cells) |
| Basophilia/Eosinophilia | Present (characteristic) | Absent |
| Prognosis | Responds well to Imatinib (TKI); median survival >10 years | Indolent; variable (some never need treatment; Richter's transformation = poor) |
| Treatment | Imatinib (BCR-ABL tyrosine kinase inhibitor) | Watchful waiting / FCR (Fludarabine + Cyclophosphamide + Rituximab) / BTK inhibitors |
Essay Q2. Tabulate differences between Hodgkin and Non-Hodgkin Lymphoma (including clinical features, histology, immunophenotype) (5 marks)
| Feature | Hodgkin Lymphoma (HL) | Non-Hodgkin Lymphoma (NHL) |
|---|
| Age | Bimodal: 15-35 yrs and >55 yrs | Any age; increases with age |
| Sex | Male > Female (except nodular sclerosis = equal) | Male > Female |
| Nodal involvement | Usually localized to a single axial group (cervical, mediastinal, para-aortic) | Multiple peripheral nodes; widespread at presentation |
| Spread | Contiguous/orderly spread (stage to stage) | Non-contiguous (skip lesions) |
| Mediastinal involvement | Common (especially nodular sclerosis) | Less common |
| Mesenteric nodes / Waldeyer's ring | Rarely involved | Commonly involved |
| Extranodal involvement | Rare | Common (bone marrow, GI tract, CNS, skin) |
| B symptoms (fever, night sweats, weight loss) | Common (30-40%) | Less common |
| Histology | Reed-Sternberg cells on background of reactive cells (lymphocytes, eosinophils, plasma cells) | No RS cells; sheets of neoplastic lymphoid cells |
| Hallmark cell | Reed-Sternberg (RS) cell - owl-eye nucleoli | No specific cell; varies by subtype |
| Immunophenotype | CD15+, CD30+, CD45-, B/T markers negative (classic HL) | CD20+ (B-cell NHL most common); CD3+ (T-cell NHL) |
| Bone marrow involvement | Late, uncommon | Early, common |
| EBV association | Yes (mixed cellularity subtype especially) | Some (Burkitt lymphoma - EBV strongly associated) |
| Subtypes | 5 WHO subtypes (NLPHL + 4 classic) | >60 subtypes (WHO classification) |
| Prognosis | Generally better; >80% cure with chemo-radiation | Variable; some indolent, some aggressive |
| Treatment | ABVD chemotherapy + radiation | Depends on subtype: R-CHOP most common |
Essay Q3. Describe differences between Myeloblasts and Lymphoblasts (with labelled diagrams) (5 marks)
Differences Table:
| Feature | Myeloblast | Lymphoblast |
|---|
| Size | Large (15-20 µm) | Small to medium (10-18 µm) |
| Nucleus | Round/oval; fine chromatin; 2-5 prominent nucleoli | Round/oval; coarse/clumped chromatin; 1-2 indistinct nucleoli |
| Cytoplasm | Moderate; Auer rods (pink needle-like inclusions) present in AML | Scanty; no Auer rods |
| Granules | Azurophilic (primary) granules present | No granules (agranular) |
| N:C ratio | Lower (more cytoplasm) | High N:C ratio (very little cytoplasm) |
| Special stains | MPO (Myeloperoxidase) POSITIVE; Sudan Black B positive | MPO negative; PAS positive (block positivity) |
| Immunophenotype | CD13+, CD33+, CD117+, MPO+ | CD19+, CD10+, TdT+ (B-ALL) OR CD2+, CD7+, TdT+ (T-ALL) |
| Disease | Seen in AML (Acute Myeloid Leukemia) | Seen in ALL (Acute Lymphoblastic Leukemia) |
| Auer rods | Present (pathognomonic of AML) | Absent |
Diagram to draw:
MYELOBLAST LYMPHOBLAST
_____ ___
/ \ / \
| [NUC] | ← Large nucleus |[NUC]| ← Smaller, clumped
\ 2-5 / with prominent \ 1-2/ chromatin, 1-2
nucleoli nucleoli nucleoli
/~~~~~\ /~~~~~\
| MPO+ | | TdT+ |
|granules| | | ← Scanty cytoplasm
\_____/ \_____/
Auer rods No Auer rods
present!
Key exam trick - Auer rods = AML = Myeloblast. If you see Auer rods in a question, diagnosis is AML.
Essay Q4. Laboratory findings in Chronic Myeloid Leukemia - CML (with peripheral smear and bone marrow diagrams) (5 marks)
Clinical features briefly:
- Middle-aged patient, insidious onset
- Massive splenomegaly (most striking feature)
- Weight loss, fatigue, night sweats, abdominal fullness
Laboratory Findings:
1. Complete Blood Count (CBC):
- WBC: Markedly elevated, often >1,00,000/cumm (can reach 5,00,000/cumm)
- Hb: Decreased (normocytic normochromic anemia)
- Platelets: Initially normal or elevated; decreased in blast crisis
2. Peripheral Blood Smear:
- Full myeloid spectrum - all stages from myeloblasts to mature neutrophils (promyelocytes, myelocytes, metamyelocytes, bands, segmented neutrophils)
- Basophilia (characteristic - absolute basophil count elevated)
- Eosinophilia
- Myeloblasts <10% in chronic phase
- Thrombocytosis (increased platelets) may be seen early
3. Bone Marrow:
- Hypercellular (100% cellularity - "packed marrow")
- Granulocytic hyperplasia - all myeloid stages
- Increased megakaryocytes (dwarf megakaryocytes)
- Fat spaces absent
- Myeloblasts <10% in chronic phase; 10-19% = accelerated phase; ≥20% = blast crisis
4. Leukocyte Alkaline Phosphatase (LAP) score:
- Markedly DECREASED / Low (differentiates CML from leukemoid reaction, where LAP is high)
5. Cytogenetics:
- Philadelphia chromosome - t(9;22)(q34;q11) in 95% of patients
- Creates BCR-ABL fusion gene → constitutively active tyrosine kinase → uncontrolled proliferation
6. Serum:
- Elevated uric acid (from cell turnover)
- Elevated LDH, vitamin B12 levels
- Elevated serum muramidase (lysozyme)
Peripheral Smear Diagram:
CML Peripheral Smear - showing "myeloid spectrum":
[Myeloblast][Promyelocyte][Myelocyte][Metamyelocyte][Band][Neutrophil]
+ Basophils (characteristic!) + Eosinophils
Phases of CML (mention in exam for extra marks):
| Phase | Blasts | Features |
|---|
| Chronic | <10% | Manageable, responds to imatinib |
| Accelerated | 10-19% | Progressive disease |
| Blast crisis | ≥20% | AML or ALL-like; poor prognosis |
QUICK REVISION SUMMARY TABLE
| Disease | Key Cell/Finding | Marker | Treatment |
|---|
| Hodgkin Lymphoma | Reed-Sternberg cell ("owl eye") | CD15+, CD30+ | ABVD |
| CLL | Smudge cells + mature lymphocytes | CD5+, CD19+, CD23+ | FCR / Ibrutinib |
| CML | Full myeloid spectrum + basophilia + Philadelphia chromosome | BCR-ABL, LAP low | Imatinib |
| ITP | Thrombocytopenia + anti-platelet IgG | Normal/↑ megakaryocytes in marrow | Steroids → IVIG → Splenectomy |
| Infectious Mononucleosis | Atypical lymphocytes | EBV, Monospot test | Supportive |
| Hemophilia A | Prolonged APTT, normal PT | Factor VIII deficiency | Factor VIII replacement |